Navigation Links
Erectile dysfunction drug may benefit cardiac function in young patients with heart defects
Date:5/8/2012

Sildenafil, also known as the erectile dysfunction drug Viagra, may give a boost to underdeveloped hearts in children and young adults with congenital heart defects. Researchers from The Children's Hospital of Philadelphia report that sildenafil significantly improved echocardiographic measures of heart function in children and young adult survivors of single ventricle heart disease palliation.

"Although researchers will need to evaluate clinical benefits over a longer period with a larger number of patients, this finding offers a potential advance in the management of patients with these types of heart defects," said study leader David J. Goldberg, M.D., a pediatric cardiologist at The Children's Hospital of Philadelphia.

The study appeared online recently in the journal Pediatric Cardiology.

The researchers randomly assigned 27 children and young adults at Children's Hospital to receive either sildenafil or a placebo for six weeks. After a six-week break in treatment, the subjects were switched to the opposite treatment course. The study team used echocardiograms to measure myocardial performance index (MPI), an indicator of the heart's overall ability to pump blood.

The patients in this double-blind, short-term study, who had a mean age of 14.9 years, had undergone a Fontan operation in early childhood, a mean of 11.3 years previously. The Fontan surgery redirects blood circulation in patients born with a severely underdeveloped ventricle, one of the heart's two pumping chambers. The operation is the third in a staged series of surgeries for life-threatening single-ventricle defects.

Although surgical advances over the past 20 years have dramatically improved survival for single-ventricle defects, patients with the condition continue to have long-term illness and risk of early death. The staged surgeries do not recreate normal heart circulation, but instead redirect blood flowing from the veins directly to the lungs, bypassing the heart. However, blood vessels in the lungs develop resistance to this blood, often reducing a patient's ability to tolerate exercise.

Sildenafil, which reduces blood vessel resistance to the flow of blood, is already used to treat pulmonary hypertension (high blood press in lung vessels), as well as erectile dysfunction. Because sildenafil has also shown promise as a treatment for adults with heart failure, the Children's Hospital researchers are exploring whether it may benefit younger patients with certain types of congenital heart disease.

The current study is part of a broader phase 2 clinical trial at The Children's Hospital of Philadelphia, the Sildenafil After the Fontan Operation (SAFO) trial. A previous study from the same research team, published in March 2011, found improvements in exercise performance, as measured by ventilator efficiency, in children and young adults with single-ventricle disease who took sildenafil compared to those who took placebo.

The current study was the first to show that sildenafil improved echocardiographic measures of ventricular performance in children and young adults with single-ventricle physiology. The biological mechanisms that affect ventricular performance are not fully understood, said Goldberg, but he noted that studies in other patients with heart disease suggest that inhibiting the abnormally high levels of the enzyme phosphodiesterase E5 (PDE5) may produce the physiological benefits seen in the single-ventricle patients.

Goldberg cautioned that further research should be pursued to determine if the observed improvements in ventricular performance persist beyond the short term and if they provide clear quality-of-life benefits. "If sildenafil is safe over the medium and long-term, and if it produces durable functional improvements, patients with single-ventricle heart disease could have their first effective long-term treatment," he added.


'/>"/>
Contact: Joey McCool Ryan
McCool@email.chop.edu
267-426-6070
Children's Hospital of Philadelphia
Source:Eurekalert

Related medicine news :

1. Erectile dysfunction study shows high prevalence of peripheral neuropathy
2. Erectile dysfunction increases with use of multiple medications
3. Erectile Dysfunction May Be Linked With Cardiovascular Trouble
4. Protecting Heart May Improve Erectile Dysfunction
5. When erectile dysfunction isnt whole story
6. Antioxidants of growing interest to address infertility, erectile dysfunction
7. Non-steroidal anti-inflammatory drugs linked to increased risk of erectile dysfunction
8. Link established between erectile dysfunction and calcified coronary arteries
9. Drug now used to treat erectile dysfuncton may enhance delivery of herceptin to certain brain tumors
10. Preoperative MRI assists in surgical planning and helps spare erectile function after RALP
11. Real Men Don't Take Erectile Dysfunction Drugs Without a Prescription
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Providing broad access to ... opposition, but there is a better way to address this problem. , That was ... Pharmacy, Public Policy and Economics at the University of Southern California, who served as ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Brady ... that its B-595 and B-7569 vinyl label materials received certification ... warning labels are tested to remain intact and legible, for use on chemical drums ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... been named Agency of Record (AOR) for Theravent, Inc. , the makers ... Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand distribution in ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... products, announced an exciting new partnership with the highly regarded and well renowned ... Management’s highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize ...
(Date:4/21/2017)... Salt Lake City, UT (PRWEB) , ... April 21, 2017 , ... ... medical staffing solutions, recently partnered with Advanced Patient Care of Utah (APCUT) and has ... the way for the next chapter of growth for our agency and our ability ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 6.35% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/18/2017)... Research and Markets has announced the addition of the ... Radiopharmaceuticals Market, Forecast to 2023" report to their offering. ... This report assesses ... growth in the number of unit shipments over the next ... design and manufacture molecular imaging equipment. Market ...
Breaking Medicine Technology: